FDA Panel Recommends Approval for Novartis CAR-T Cell Therapy
FDA Panel Recommends Approval for Novartis CAR-T Cell Therapy
A breakthrough cancer treatment is one step closer to regulatory approval.
The U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee unanimously voted to recommend approval for CTL019, an experimental cancer drug that belongs to a class of drugs called CAR T-cell therapies, which is a form of immunotherapy that essentially takes control of the body’s T-cells and directs them to attack tumors. …